Finance

Lists
4534:TYO
Mochida Pharmaceutical Co Ltd
Â¥3,180.00
0.00%
(0.00) 1D
Sep 9, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4534...
Mkt. cap
115.72B
Avg. vol.
54.55K
Volume
0.00
Dividend
2.52%
Quarterly dividend
Â¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
12.27
52-wk high
Â¥3,965
52-wk low
Â¥2,929
EPS
Â¥259
Shares outstanding
19.85M
No. of employees
1K
Mkt. cap
115.72B
Avg. vol.
54.55K
Volume
0.00
Dividend
2.52%
Quarterly dividend
Â¥20
Ex-dividend date
Sep 29, 2026
P/E ratio
12.27
52-wk high
Â¥3,965
52-wk low
Â¥2,929
EPS
Â¥259
Shares outstanding
19.85M
No. of employees
1K
Profile
Mochida Pharmaceutical Co., Ltd is a Japanese pharmaceutical company. One of its products is the antidepressant setiptiline. Wikipedia
About Mochida Pharmaceutical Co Ltd
CEO-
Employees1.48K
FoundedApr 28, 1945
HeadquartersShinjuku City, Tokyo, Japan
SectorPharmaceutical industry
Websitemochida.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
28.35B
32.50B
29.46B
31.72B
Cost of goods sold
15.13B
17.50B
15.06B
17.03B
Cost of revenue
15.13B
17.50B
15.06B
17.03B
Research and development expenses
-
-
12.16B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.83B
12.45B
-376.00M
11.12B
Operating expense
10.83B
12.45B
11.78B
11.12B
Total operating expenses
25.96B
29.94B
26.84B
28.15B
Operating income
2.40B
2.56B
2.62B
3.56B
Other non operating income
31.00M
-67.00M
12.00M
34.00M
EBT including unusual items
2.40B
3.17B
2.82B
4.86B
EBT excluding unusual items
2.40B
3.17B
2.85B
4.19B
Income tax expense
435.00M
681.00M
1.26B
1.69B
Effective tax rate
18.15%
21.50%
44.72%
34.68%
Other operating expenses
-
-
-
-
Net income
1.96B
2.49B
1.56B
3.18B
Net profit margin
6.92%
7.65%
5.30%
10.02%
Earnings per share
-
-
-
-
Interest and investment income
42.00M
232.00M
42.00M
297.00M
Interest expense
-1.00M
-29.00M
-42.00M
-43.00M
Net interest expenses
41.00M
203.00M
-
254.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.11B
-
3.37B
4.31B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps